REG - Aptamer Group PLC - Trading Update

AptamerAnnouncement

05/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230505:nRSE5008Ya&default-theme=true

RNS Number : 5008Y  Aptamer Group PLC  05 May 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET
ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").

 

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Trading Update

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, today announces a trading
update for the year ending 30 June 2023.

 

Revenue for the ten months ended 30 April 2023
was approximately £1.4m (unaudited) as the existing pipeline of new
business has taken longer than expected to convert, especially licensing
and royalty-based contracts, against a backdrop of continuing market
headwinds.

 

The Group now expects full year revenues to be materially below FY2022. The
sales pipeline remains healthy across both fee-for-service and licensing, and
while the Group expects some of this to be recognised as revenue in the
current financial year, the majority, if converted, will fall into the next
financial year.

 

As of 30 April 2023, the Group cash balance was £0.7m. The Group is making
cost savings in order to extend the cash runway. As noted in the half year
results, continuing reduced revenues would mean that the Group would need to
raise working capital. The Board is exploring a range of funding options
including non-dilutive and dilutive sources to strengthen the balance sheet,
which would also provide a stronger negotiating position with potential new
business opportunities.

 

Further updates will be provided as appropriate.

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley
                            +44 (0) 1904 217 404

 

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Mark Brady / Adam Dawes
                      +44 (0) 20 3368 3550

 

Liberum Capital Limited - Broker

Phil Walker / Richard Lindley / Ben Cryer / Cara Murphy     +44 (0) 20
3100 2000

 

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone                 +44 (0)
20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support discovery
and development across the Life Sciences.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTNKQBPCBKDBPK